EiRx, BioMérieux Pen PGx Alliance to Validate Each Other’s Dx, Rx Biomarkers

Jul 13, 2006

NEW YORK (GenomeWeb News) — EiRx Therapeutics and BioMérieux today said they plan to validate the diagnostic and therapeutic potential of their candidate tumor markers.

Terms of the alliance call for BioMérieux to see if proteins in EiRx’s biomarker panel can become components in new diagnostics for colorectal cancer. Meanwhile, EiRx will use its siRNA-driven platform to test BioMérieux’s colorectal biomarker panel as targets for new drug therapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not a Unique Challenge Anymore

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Case Goes On

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

The Very Old, Very Young, and Very Talented

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

This Week in PLOS

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Main menu